Cargando…

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib

SIMPLE SUMMARY: The mRNA expression of nine previously described genes that may affect resistance to multiple myeloma (MM), viz., ABCB1, CXCR4, MAF, MARCKS, POMP, PSMB5, RPL5, TXN, and XBP1, was compared between bortezomib-refractory and bortezomib-sensitive patients. RPL5 was the only gene to be si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robak, Pawel, Jarych, Dariusz, Mikulski, Damian, Dróżdż, Izabela, Węgłowska, Edyta, Kotkowska, Aleksandra, Misiewicz, Małgorzata, Smolewski, Piotr, Stawiski, Konrad, Fendler, Wojciech, Szemraj, Janusz, Robak, Tadeusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956525/ https://www.ncbi.nlm.nih.gov/pubmed/33668794 http://dx.doi.org/10.3390/cancers13050951

Ejemplares similares

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Paweł, et al.
Publicado: (2020)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Puła, Anna, et al.
Publicado: (2023)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS.
por: Puła, A., et al.
Publicado: (2022)

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
por: Yang, Yan, et al.
Publicado: (2022)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
por: Allmeroth, Kira, et al.
Publicado: (2020)

PSMB2 and RPL32 are suitable denominators to normalize gene expression profiles in bronchoalveolar cells
por: Kriegova, Eva, et al.
Publicado: (2008)

Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (2004)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
por: Wu, Dong, et al.
Publicado: (2021)

Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
por: Klonowska-Szymczyk, Agnieszka, et al.
Publicado: (2014)

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation
por: Mikulski, Damian, et al.
Publicado: (2023)

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
por: Hofman, Isabel JF, et al.
Publicado: (2016)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
por: Mikulski, Damian, et al.
Publicado: (2022)

PSMB5 overexpression is correlated with tumor proliferation and poor prognosis in hepatocellular carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Sequence Variants in PSMB8/PSMB9 Immunoproteasome Genes and Risk of Urothelial Bladder Carcinoma
por: Elhawary, Nasser A, et al.
Publicado: (2023)

Identification of RPL5 and RPL10 as novel diagnostic biomarkers of Atypical teratoid/rhabdoid tumors
por: Ren, Yanming, et al.
Publicado: (2018)

Genetic Variants of RPL5 and RPL9 Genes among Saudi Patients Diagnosed with Thrombosis
por: Hassan, Fathelrahman Mahdi, et al.
Publicado: (2021)

Identification of PSMB5 as a genetic modifier of fragile X–associated tremor/ataxia syndrome
por: Kong, Ha Eun, et al.
Publicado: (2022)

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress
por: Han, Tao, et al.
Publicado: (2022)

Nucleoside 5′-O-monophosphorothioates as modulators of the P2Y14 receptor and mast cell degranulation
por: Gendaszewska-Darmach, Edyta, et al.
Publicado: (2016)

Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells
por: Chen, Nan-Xiang, et al.
Publicado: (2020)

PSMB5 Alleviates Ulcerative Colitis by Inhibiting ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis
por: Han, Liang, et al.
Publicado: (2022)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers
por: Geoffroy, Karen, et al.
Publicado: (2023)

S2.5 The nutritional approach to Pompe disease
por: Esposito, Katia, et al.
Publicado: (2011)

Retracted: PSMB5 Alleviates Ulcerative Colitis by Inhibiting ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis
por: Markers, Disease
Publicado: (2023)

Differentiation of preadipocytes and mature adipocytes requires PSMB8
por: Arimochi, Hideki, et al.
Publicado: (2016)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells
por: Zhang, Shunrong, et al.
Publicado: (2021)

1,4-dihydropyridine Derivatives Increase mRNA Expression of Psma3, Psmb5, and Psmc6 in Rats
por: Dišlere, Kristīne, et al.
Publicado: (2021)

Rpl5-Inducible Mouse Model for Studying Diamond-Blackfan Anemia
por: Kazerounian, Shideh, et al.
Publicado: (2019)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_go724i83h2vtts4c29brgkbpua